Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Saved in:
Bibliographic Details
Title: Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
Authors: Di Pietro A; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Au L; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Crock P; Bioinformatics, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Thio N; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Bioinformatics, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Pizzolla A; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Nguyen TN; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Macdonald S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Chalmers H; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Zhu R; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Airaghi A; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Molden-Hauer T; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Bacac M; Roche Innovation Center, Zurich, Switzerland., Schwalie P; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Schlenker R; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Levesque MP; Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Mailer S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Melanoma Research Victoria, Melbourne, VIC, Australia.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Barnes-Cullen K; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Melanoma Research Victoria, Melbourne, VIC, Australia.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Winch K; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Melanoma Research Victoria, Melbourne, VIC, Australia.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Chan J; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Yeung GA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Spain L; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Rao AD; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Gyorki DE; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., McArthur GA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Melanoma Research Victoria, Melbourne, VIC, Australia.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Mackay LK; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Neeson PJ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. paul.neeson@petermac.org.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. paul.neeson@petermac.org.
Source: Nature communications [Nat Commun] 2026 Jun 11. Date of Electronic Publication: 2026 Jun 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-74076-y